Evidence map›Paper›PMID 40676834›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8

Yanyang Nan, Min Zhu, Qian Wang, Xiaoxue Du, Caili Xu, Yuping Huang, Yujie Liu, Shaoyuan Zhou, Yuluoyan Qiu, Xiao Chu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. IL-18-Mediated Tumor Immune Evasion.Current issues in molecular biology · 2026
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yanyang NanDepartment of Biological Medicines, School of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Min ZhuShanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai 201318, China.
Qian WangDepartment of Biological Medicines, School of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Xiaoxue DuDepartment of Biological Medicines, School of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Caili XuDepartment of Biological Medicines, School of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Yuping HuangShanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai 201318, China.
Yujie LiuDepartment of Biological Medicines, School of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Shaoyuan ZhouDepartment of Biological Medicines, School of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Yuluoyan QiuShanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai 201318, China.
Xiao ChuDepartment of Thoracic Surgery, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China. Electronic address: chuxiao@fudan.edu.cn.
Dianwen JuDepartment of Biological Medicines, School of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China. Electronic address: dianwenju@fudan.edu.cn.
Yakun WanShanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai 201318, China. Electronic address: ykwan@novamab.com.
Xuyao ZhangDepartment of Biological Medicines, School of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China; Quzhou Fudan Institute, Quzhou 324002, China. Electronic address: xuyaozhang@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokines are promising in cancer immunotherapy, but their pleiotropic effects limit specificity and clinical utility. Through binding to IL-18Rα and IL-18Rβ, interleukin-18 (IL-18) stimulates innate lymphocytes and effector T cells for antitumor immunity. However, clinical trials of recombinant IL-18 have been hampered by IL-18 binding protein (IL-18BP), a secreted high-affinity decoy receptor. Here, we developed decoy-resistant bispecific nanobodies that maintain IL-18 signaling potential. Based on agonistic nanobodies targeting IL-18Rα and IL-18Rβ, bispecific nanobody A4B2-mdFc effectively enhanced CD8

Indexed as

Antibodies, BispecificCD8-Positive T-LymphocytesInterleukin-18NeoplasmsSingle-Domain AntibodiesAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansImmunotherapyIntercellular Signaling Peptides and ProteinsMiceXenograft Model Antitumor AssaysAntibodies, BispecificIntercellular Signaling Peptides and ProteinsInterleukin-18interleukin-18 binding proteinSingle-Domain Antibodiesbispecific antibodycytokine mimeticIL-18immunotherapynanobody

Identifiers

PMID40676834
PMCPMC12848198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.